Exchange: NASDAQ·Updated 04:25 PM EST

OBIO News

News
all
press releases
Orchestra BioMed (NASDAQ:OBIO) Earns Buy Rating from B. Riley Financial
B. Riley Financial reaffirmed a "buy" rating and issued a $12.00 target price (up from $11.00) on shares of Orchestra BioMed in a report on Friday...
MarketBeat
Orchestra BioMed (NASDAQ:OBIO) Earns Buy Rating from B. Riley Financial
B. Riley Financial reaffirmed a "buy" rating and issued a $12.00 target price (up from $11.00) on shares of Orchestra BioMed in a report on Friday...
MarketBeat
More News
Advanced AI Platforms Are Helping Researchers Identify New Cancer Targets, Engineer Promising Peptides, and Accelerate Next-Generation Drug Development   New York, NY – November 18, 2026 – Artificial intelligence is giving cancer researchers a powerful new way to find potential drug targets and develop treatments that may have been difficult or time-consuming to discover using […] The post How AI and Anticancer Peptides Could Reshape the Future of Cancer Treatment appeared first on Financial News Media.
Financial News Media
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - Research analysts at HC Wainwright increased their FY2026 earnings estimates for shares of Orchestra BioMed in a report released on Friday, November 13th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per...
MarketBeat
The mean of analysts' price targets for Orchestra BioMed Holdings, Inc. (OBIO) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +25.00% and -17.27%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Guardant Health (GH) delivered earnings and revenue surprises of 0.00% and +2.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks
Orchestra BioMed received an upgrade from BTIG while LifeStance Health Group received a price target hike from Barclays.
Stocktwits
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -8.57% and -32.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
(RTTNews) - Orchestra BioMed Holdings, Inc. (OBIO) announced Loss for second quarter of -$24.079 million...
Nasdaq News: Markets

Advertisement|Remove ads.